Navigation Links
Munich researchers discover new target for tailored antibiotics
Date:7/14/2009

This release is available in German.

More and more strains of bacteria are developing resistance to previously life-saving antibiotics. Researchers at TUM, the Technische Universitaet Muenchen, have shed light on a metabolic step that appears in many aggressive microorganisms -- such as tuberculosis and malaria pathogens -- and that may provide a promising target for a new class of antibiotics. The researchers present their results in the chemistry journal Angewandte Chemie.

Antibiotics can hold harmful pathogens in check by interfering with their ability to produce essential compounds. Ever more bacterial strains are developing multiple antibiotic resistances, however, rendering previously life-saving medications ineffective. That is why researchers around the world are searching for new reaction steps that are vital to microorganisms but play no relevant role in humans. Professor Michael Groll, Dr. Jrg Eppinger, and Dr. Tobias Grwert, biochemists at the Technische Universitt Mnchen, and their research team have described in detail the structural basis for just such a reaction step.

The cells of virtually all life forms synthesize essential natural substances belonging to the class of terpenes and steroids from the small isoprene building blocks dimethylallyl pyrophosphate (DMAPP) and isopentenyl pyrophosphate (IPP). Mammals and a large number of other organisms generate these essential metabolites via the so-called mevalonate pathway. But most human pathogens, including Plasmodium falciparum, have developed an alternate mechanism for producing these important substances. Now, this special pathway may spell doom for those bacteria. The TUM researchers have unraveled the structural basis of the terminal step in bacterial isoprene synthesis. The crucial enzyme has a most unusual structure, similar to a three-leaf clover, and m
'/>"/>

Contact: Dr. Andreas Battenberg
battenberg@zv.tum.de
49-892-891-2890
Technische Universitaet Muenchen
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Munich researchers discover key allergy gene
2. 2 Alexander von Humboldt professorships go to LMU Munich
3. Researchers identify proteins involved in new neurodegenerative syndrome
4. Texas researchers and educators head for Antarctica
5. MGH researchers describe new way to identify, evolve novel enzymes
6. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
7. U of MN researchers discover noninvasive diagnostic tool for brain diseases
8. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
9. Researchers discover new strategies for antibiotic resistance
10. Researchers find new taste in fruit flies: carbonated water
11. Binghamton University researchers investigate evolving malaria resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... the greatest risk to Europe based upon a proxy ... researchers using a ,big data, approach to scientific research. ... and Global Health ranked the top 100 pathogens affecting ... a system which, they believe, will help governments across ... of infectious diseases, including as a result of climate ...
(Date:8/27/2014)... 2014 /PRNewswire-iReach/ -- The IEEE Engineering in Medicine and ... Annual International Conference (EMBC,14), this year being held at ... Chicago, Illinois , from Tuesday, August 26 through ... and industry professionals in science, medicine, and engineering are ... This year,s conference theme is ...
(Date:8/27/2014)... is available in German . ... the most common inherited disease affecting the peripheral nervous ... Max Planck Institute of Experimental Medicine and University Medical ... cells is impaired in rats with the disease. These ... known as myelin, which facilitates the rapid transfer of ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Potential therapy for incurable Charcot-Marie-Tooth disease 2
... young scientists have received postdoctoral fellowships from the National ... they conduct research with the eventual aim of protecting ... mentorship from a faculty member at their home institution, ... research teams. This allows them to interact with some ...
... from a pivotal, large-scale Phase III trial, published online ... , show that the RTS,S malaria vaccine candidate can ... immunization with a control vaccine, infants (aged 6-12 weeks ... episodes of both clinical and severe malaria and had ...
... Nearly 3,000 insect scientists are expected to attend Entomology 2012, ... this November in Knoxville, TN. Members of the media who ... press pass. WHEN: November 11-14, 2012 ... WHAT: Entomology 2012 is the 60th Annual ...
Cached Biology News:Space research institute awards postdoctoral fellowships to 4 scientists 2RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 2RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 3RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 4
(Date:8/27/2014)... Aug. 27, 2014 Guggenheim Securities, the investment ... announced the hiring of veteran equity analyst Charles "Tony" ... Mr. Butler will focus on the biotech/biopharma sector. ... wealth of experience and a broad network of relationships ... Managing Director and Head of Equities at Guggenheim Securities. ...
(Date:8/27/2014)...  ARCH Venture Partners, one of the largest ... of seed and early-stage advanced technology companies, today ... more than $400 million in subscriptions. ARCH Venture ... by more than $150 million. "The ... potential of our approach to finding and funding ...
(Date:8/27/2014)... City, OR (PRWEB) August 27, 2014 ... Report, “Consolidation continues to reshape the look and feel ... nutrition. Consumer demand for higher-quality ingredients will push for ... North American market have experienced strong market growth in ... ethical attributes in their food and cosmetics to fit ...
(Date:8/26/2014)...  NeuroSigma, Inc., a Los Angeles ... today announced that it has filed a registration statement ... Commission relating to a proposed initial public offering of ... offered and the price range for the proposed offering ... will act as the book-running manager for the proposed ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... sizes and shapes, scientists now understand how they lose ... weighing any single atom. Such ultrasensitive measurements could ... and diagnostics, enabling the detection of minuscule disease-causing agents ... level. Researchers are interested in nanosized materials because ...
... ... , ... CA (Vocus) - GreenHouse announced today that on July 30, 2009 it will introduce ... a high performance ethanol fuel for cars. The first installation of the E-Fuel ...
... , , , ... Calif. and LONDON, July 27 Amgen (Nasdaq: AMGN ... companies will share commercialization of Amgen,s monoclonal antibody denosumab for postmenopausal ... product is approved in these countries. Amgen will commercialize the ...
Cached Biology Technology:1 nano-step closer to weighing a single atom 2GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles 2GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 7